Posts by: admin

admin

September 11, 2014September 11, 2014

Celsion Announces Study Highlights from the International Liver Cancer Association 2014 Annual Conference

News

Celsion Corporation, an oncology drug development company, has announced the highlights from three presentations made by the principal investigators in the Company’s pivotal Phase III, global pivotal, double-blind, placebo-controlled OPTIMA ... Read more

September 9, 2014September 9, 2014

Merck Receives Accelerated Approval For KEYTRUDA

News

Merck & Co. has announced that the U.S. Food and Drug Administration (FDA) has given KEYTRUDA® (pembrolizumab) an approved acceleration at a dose of 2 mg/kg every three weeks for ... Read more

September 8, 2014September 8, 2014

Novel Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients

News

Researchers from the University of Texas MD Anderson Cancer Center presented a new breast cancer immunotherapy vaccine candidate, GP2, at the 2014 American Society of Clinical Oncology’s Breast Cancer Symposium in San ... Read more

September 5, 2014September 5, 2014

“Ludwig Cancer Research and CRI collaborate on VentiRx’s investigational immunotherapy”

News

VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company developing novel Toll-like receptor 8 (TLR8) drugs, has announced it is partnering with the Ludwig Cancer Research and the Cancer Research Institute (CRI) ... Read more

September 3, 2014September 3, 2014

New Protein Adjuvant for Dendritic Cell-Based Tumor Immunotherapy

News

In a new study entitled, “A Potential Protein Adjuvant Derived from Mycobacterium tuberculosis Rv0652 Enhances Dendritic Cells-Based Tumor Immunotherapy” and published in the PLOSOne journal, a group of researchers from Konkuk University, ... Read more

September 2, 2014September 2, 2014

Motolimod Receives Fast Track Designation as Immunotherapy for Women with Ovarian Cancer

News

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel Toll-like receptor 8 (TLR8) immunotherapies, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation ... Read more

August 28, 2014August 28, 2014

Low Dose Naltrexone-based Lodonal Ships to Panama, Malawi For Cancer Treatment

News

TNI BioTech Inc., a biotechnology company developing innovative therapies for autoimmune diseases in emerging nations, has announced it will make its first shipments of Lodonal® to the Republic of Panama ... Read more

August 27, 2014August 27, 2014

Merck’s Cancer Immunotherapy Drug Pembrolizumab Likely To Get Early FDA Approval, According to Report

News

Merck & Co’s anticipated immunotherapy pembrolizumab is likely to be approved before October by the U.S. Food and Drug Administration (FDA) as a treatment for melanoma, making it the first ... Read more

August 26, 2014August 26, 2014

PD-L1 (SP142) Antibody Developed By Spring Bioscience To Be Studied As Cancer Immunotherapy

News

A new PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody developed as a part of Roche/Genentech’s anti-PD-L1 (MPDL3280A) immunotherapy program has been released commercially by Spring Bioscience (Spring), a member of ... Read more

August 25, 2014August 25, 2014

Checkpoint Inhibitors in Immunotherapy Show Promise for Lung Cancer

News

Recent studies presented at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO) indicate that checkpoint inhibitors used as a combination therapy can become the future for ... Read more